"The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.
MCL is a rare form of non-Hodgkin lymphoma and represents about 6 "...
Campath Patient Information including How Should I Take
In this Article
- What is alemtuzumab (Campath)?
- What are the possible side effects of alemtuzumab (Campath)?
- What is the most important information I should know about alemtuzumab (Campath)?
- What should I discuss with my health care provider before receiving alemtuzumab (Campath)?
- How is alemtuzumab given (Campath)?
- What happens if I miss a dose (Campath)?
- What happens if I overdose (Campath)?
- What should I avoid while receiving alemtuzumab (Campath)?
- What other drugs will affect alemtuzumab (Campath)?
- Where can I get more information?
What should I discuss with my health care provider before receiving alemtuzumab (Campath)?
You should not receive alemtuzumab if you are allergic to it.
To make sure alemtuzumab is safe for you, tell your doctor if you have any of these other conditions:
- any type of bacterial, fungal, or viral infection (including herpes, cytomegalovirus, HIV, or AIDS);
- if you are allergic to mouse or hamster proteins; or
- if you have regular blood transfusions.
FDA pregnancy category C. It is not known whether alemtuzumab will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while receiving this medication.
It is not known whether alemtuzumab passes into breast milk or if it could harm a nursing baby. You should not breast-feed while you are receiving alemtuzumab.
How is alemtuzumab given (Campath)?
Alemtuzumab is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting. Alemtuzumab must be given slowly, and the IV infusion can take up to up to 2 hours to complete.
This medication is usually given for a total or 12 weeks. You may receive the medication every day or 3 days per week, depending on any side effects that occur.
If you have stopped receiving alemtuzumab for longer than 7 days for any reason, you may need to restart the medication at a lower dose.
You may be given an antibiotic and other medications to help prevent certain side effects of alemtuzumab. Take these medicines for the full prescribed length of time, which may include at least 2 months after you stop receiving alemtuzumab.
Alemtuzumab can lower blood cells that help your body fight infections and help your blood to clot. Your blood will need to be tested often. Your cancer treatments may be delayed based on the results of these tests. Visit your doctor regularly.
Additional Campath Information
- Campath Drug Interactions Center: alemtuzumab iv
- Campath Side Effects Center
- Campath Overview including Precautions
- Campath FDA Approved Prescribing Information including Dosage
Campath - User Reviews
Campath User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.